Blog

TOTAL:  QUESTION 1 (10)

Which of the following serologic markers for Hepatitis B, if positive, would indicate continued presence of the virus?

In the State of Ohio, one of the newborn screen tests is polymerase chain reaction (PCR) for the DNA excision circles that are generated during the D-J and V-D gene rearrangements of the beta chain of the T-cell receptor.  This newborn screening test is screening for which of the following diseases:

A patient presents to his doctor three weeks after the start of an acute illness that clinically resembled infectious mononucleosis.  The heterophile antibody test is negative, and the components of a follow-up EBV (Epstein Barr Virus) serologic profile (VCA IgM, VCA IgG, and EBNA IgG) are all negative.  Which of the following viruses is the most likely to have this clinical presentation and these lab findings?

Intravenous infusion of monoclonal antibodies into patients as therapeutic agents is:

Initial laboratory testing for Lyme disease involves a screening ELISA to detect the presence of antibodies to Borrelia burgdorferi.  Depending on the result, a Western blot or a different ELISA may be ordered and performed; the purpose of the Western blot or second ELISA is to:

As the result of EBV infection (infectious mononucleosis), the appearance of antibody to EBNA (EBV nuclear antigen) occurs in what timeframe:

Beginning with the use of the 4thgeneration HIV screening ELISA, HIV-1 Western blot was abandoned as the sole technique to confirm a positive screen ELISA.  Which of the following patients would be the most likely to have a true positive 4thgeneration HIV screen and a negative HIV-1 Western blot:

A CT-scan of the brain in an otherwise normal patient (that is, not immunosuppressed) reveals an apparent abscess in the brain.  This finding leads to a spinal tap to obtain cerebrospinal fluid (CSF) for lab testing.   Which of the following CSF findings would be MOST consistent with an acute (i.e., current) infection by Toxoplasma gondii in this brain abscess:

The process of producing cells for chimeric antigen receptor-T cell (CAR-T) therapy involves which one of the following manipulations of the patient’s T cells: